Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumors of Non-Pancreatic Origin”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03049189
What this trial is testing

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 324
Testing effectiveness (Phase 2)Study completedNCT02420691
What this trial is testing

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDuodenal Neuroendocrine Tumor G1Functional Pancreatic Neuroendocrine Tumor+5 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Large-scale testing (Phase 3)UnknownNCT01744249
What this trial is testing

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Who this might be right for
Neuroendocrine TumorsAdvanced Cancer
Grupo Espanol de Tumores Neuroendocrinos 255
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Study completedNCT01177397
What this trial is testing

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Who this might be right for
Multiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more
Celgene 226
116